Future oncology最新文献_第10页

Clinical benefits of deep learning-assisted ultrasound in predicting lymph node metastasis in pancreatic cancer patients. 深度学习辅助超声预测胰腺癌患者淋巴结转移的临床价值。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-06-23 DOI: 10.1080/14796694.2025.2520149

Dong-Yue Wen, Jia-Min Chen, Zhi-Ping Tang, Jin-Shu Pang, Qiong Qin, Lu Zhang, Yun He, Hong Yang

{"title":"Clinical benefits of deep learning-assisted ultrasound in predicting lymph node metastasis in pancreatic cancer patients.","authors":"Dong-Yue Wen, Jia-Min Chen, Zhi-Ping Tang, Jin-Shu Pang, Qiong Qin, Lu Zhang, Yun He, Hong Yang","doi":"10.1080/14796694.2025.2520149","DOIUrl":"10.1080/14796694.2025.2520149","url":null,"abstract":"Aim: This study aimed to develop and validate a deep learning radiomics nomogram (DLRN) derived from ultrasound images to improve predictive accuracy for lymph node metastasis (LNM) in pancreatic cancer (PC) patients.Methods: A retrospective analysis of 249 histopathologically confirmed PC cases, including 78 with LNM, was conducted, with an 8:2 division into training and testing cohorts. Eight transfer learning models and a baseline logistic regression model incorporating handcrafted radiomic and clinicopathological features were developed to evaluate predictive performance. Diagnostic effectiveness was assessed for junior and senior ultrasound physicians, both with and without DLRN assistance.Results: InceptionV3 showed the highest performance among DL models (AUC = 0.844), while the DLRN model, integrating deep learning and radiomic features, demonstrated superior accuracy (AUC = 0.909), robust calibration, and significant clinical utility per decision curve analysis. DLRN assistance notably enhanced diagnostic performance, with AUC improvements of 0.238 (p = 0.006) for junior and 0.152 (p = 0.085) for senior physicians.Conclusion: The ultrasound-based DLRN model exhibits strong predictive capability for LNM in PC, offering a valuable decision-support tool that bolsters diagnostic accuracy, especially among less experienced clinicians, thereby supporting more tailored therapeutic strategies for PC patients.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2335-2345"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12323435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US. 美国晚期卵巢癌患者2020年后一线维持治疗模式的现实世界

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-14 DOI: 10.1080/14796694.2025.2526273

Dana M Chase, Linda Kalilani, Maureen A Cooney, Zsofia Kiss, Amanda K Golembesky, Monica Kobayashi, Megha Dayma, Elif Coskuncay, Jeanne M Schilder

{"title":"Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US.","authors":"Dana M Chase, Linda Kalilani, Maureen A Cooney, Zsofia Kiss, Amanda K Golembesky, Monica Kobayashi, Megha Dayma, Elif Coskuncay, Jeanne M Schilder","doi":"10.1080/14796694.2025.2526273","DOIUrl":"10.1080/14796694.2025.2526273","url":null,"abstract":"Aims: To describe first-line maintenance (1LM) treatment patterns since 1 January 2020, for real-world patients with newly diagnosed advanced ovarian cancer (aOC).Patients & methods: This retrospective study used a US-nationwide electronic health record-derived deidentified database. Eligible patients were aged ≥ 18 years with stage III/IV epithelial OC and initiated first-line platinum-based chemotherapy±bevacizumab (index; 01Jan2020-28Feb2023). Baseline characteristics and 1LM treatment patterns were summarized overall and by BRCA status.Results: Among 599 eligible patients (median [interquartile range] age, 67 [59-74] years; 59.8% White; 50.3% stage III disease), 15.5% had BRCA-mutated (BRCAm), 72.3% BRCA wild-type (BRCAwt), and 12.2% unknown BRCA status. Overall, 289 patients (48.2%) received 1LM therapy (poly(ADP-ribose) polymerase inhibitor [PARPi] monotherapy, 23.4%; bevacizumab monotherapy, 14.7%; bevacizumab+PARPi, 7.8%; other therapies, 2.3%). PARPi monotherapy was most common among patients with BRCAm (47.3%) versus BRCAwt (21.7%) or BRCA-unknown (2.7%) status. The same was true for 1LM bevacizumab+PARPi (BRCAm, 16.1%; BRCAwt, 7.4%; BRCA-unknown, 0%). Bevacizumab monotherapy was most common among patients with BRCAwt (18.7%) versus BRCAm (3.2%) or BRCA-unknown (5.5%) status.Conclusions: Fewer than half of included patients with aOC received 1LM treatment in the real-world setting. More work is needed to understand reasons underlying real-world 1LM treatment choice for patients with aOC.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2495-2503"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of Naples prognostic score for locally advanced gastric cancer after neoadjuvant chemoimmunotherapy. 那不勒斯预后评分对局部进展期胃癌新辅助化疗免疫治疗的预后价值。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-12 DOI: 10.1080/14796694.2025.2532365

Xiong Sun, Tuo Ruan, Yao Lin, Chengguo Li, Qian Shen, Tianhao Li, Jianing Ding, Yuping Yin, Kaixiong Tao

{"title":"Prognostic value of Naples prognostic score for locally advanced gastric cancer after neoadjuvant chemoimmunotherapy.","authors":"Xiong Sun, Tuo Ruan, Yao Lin, Chengguo Li, Qian Shen, Tianhao Li, Jianing Ding, Yuping Yin, Kaixiong Tao","doi":"10.1080/14796694.2025.2532365","DOIUrl":"10.1080/14796694.2025.2532365","url":null,"abstract":"Background: The parameters of the Naples prognostic score (NPS) include albumin, total cholesterol, neutrophil-lymphocyte ratio, and lymphocyte-monocyte ratio. This study aimed to investigate the prognostic value of preoperative NPS in locally advanced gastric cancer(LAGC) patients underwent radical resection after neoadjuvant chemoimmunotherapy (NCIT).Research design and methods: The NPS was calculated and patients were then divided into two groups according to their NPS values as follows: NPS = 0-2 (group 1), NPS = 3-4 (group 2). Univariate and multivariate Cox analysis were used to identify independent prognostic factors associated with overall survival (OS), and time-dependent receiver operating characteristic (t-ROC) curves were carried to evaluate the discriminatory capacity of the prognostic scoring systems.Results: A total of 117 patients were included in this study. The 1- and 2-year OS rates in group 1 were 100.0% and 95.7%, group 2 exhibited rates of 95.7% and 84.4%. Multivariate cox analysis demonstrated that NPS was an independent prognostic factor of OS (p = 0.009). Furthermore, NPS exhibited better prognostic performance in the prediction of OS than additional prognostic scoring systems.Conclusions: NPS is a significant prognostic indicator and can be a reliable predictor of survival in LAGC patients underwent radical resection after NCIT.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2605-2613"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144617236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ESO-Shanghai 20: phase III clinical trial of anti-PD-1 therapy with local intervention for oligometastatic ESCC. ESO-Shanghai 20：局部干预抗pd -1治疗低转移性ESCC的III期临床试验

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-30 DOI: 10.1080/14796694.2025.2534770

Guangmin Mao, Zhuocheng Xin, Qingsong Fan, Huijuan Zhu, Jinjun Ye, Long Zhou, Yufeng He, Benhua Xu, Cheng Chen, Zhijun Li, Xiaowei Gu, Xianfeng Li, Xiaomin Wang, Junjun Guo, Zhengyang Xu, Peng Wan, Yunxia Zhang, Fuzheng Zhang, Canhong Huang, Qiong Yi, Jiangqiong Huang, Shixiong Liang, Junqiang Chen, Yu Lin, Qingliang Fang, Yun Chen, Dashan Ai, Hongcheng Zhu, Shengnan Hao, Qi Liu, Kuaile Zhao

引用次数: 0

Exosomes: a potential tool in the diagnosis, prognosis and treatment of patients with colorectal cancer. 外泌体：结直肠癌诊断、预后和治疗的潜在工具。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-06-14 DOI: 10.1080/14796694.2025.2520150

Azmin Akter, Tasnima Kamal, Sharmin Akter, Abdul Auwal, Farhadul Islam

{"title":"Exosomes: a potential tool in the diagnosis, prognosis and treatment of patients with colorectal cancer.","authors":"Azmin Akter, Tasnima Kamal, Sharmin Akter, Abdul Auwal, Farhadul Islam","doi":"10.1080/14796694.2025.2520150","DOIUrl":"10.1080/14796694.2025.2520150","url":null,"abstract":"Colorectal cancer (CRC), a commonly diagnosed malignancy, is one of the most frequent causes of cancer-related deaths worldwide. To effectively lower the death rate from this disease, it is essential to create public health methods, including developing new biomarkers that facilitate screening, diagnosis, prognosis, and therapy response prediction. CRC-derived Exosomes are a type of extracellular vesicle that transport functional molecules like proteins, lipids, nucleic acids (DNA, mRNA, miRNA, lncRNA, and noncoding RNA), and other metabolites, which act as molecular cargos to facilitate transportation. Exosomes generated and secreted from cancer cells are key biomarkers for early, noninvasive cancer diagnosis, prognosis, and treatment response, with their biogenesis in CRC offering molecular insights. Their expression varies across time, tissues, and disease stages. Thus, the development of innovative and effective techniques for isolating and detecting exosomes holds great potential for tumor diagnosis, prognosis prediction, and developing techniques (MSC-derived exosome, DC-derived exosome, engineered exosome, etc.) and their contents to improve the specificity and efficacy of therapies for patients with CRC. This review explores the features and formation of CRC-derived exosomes, highlighting their diagnostic, prognostic, and therapeutic significance through a comprehensive analysis of exosome extraction, identification, purification, and documented biological roles in existing literature.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2347-2365"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12323422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative efficacy of bone-modifying agents in the treatment of lung cancer bone metastases: immunotherapy era. 骨修饰剂治疗肺癌骨转移的比较疗效：免疫治疗时代。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-01 DOI: 10.1080/14796694.2025.2525744

Dongmei Sun, Hui Zhu, Qinhao Xu, Yujie Wang, Yuezheng Peng, Yaru Tian, Jinming Yu, Zhe Wang

{"title":"Comparative efficacy of bone-modifying agents in the treatment of lung cancer bone metastases: immunotherapy era.","authors":"Dongmei Sun, Hui Zhu, Qinhao Xu, Yujie Wang, Yuezheng Peng, Yaru Tian, Jinming Yu, Zhe Wang","doi":"10.1080/14796694.2025.2525744","DOIUrl":"10.1080/14796694.2025.2525744","url":null,"abstract":"Aim: Denosumab and bisphosphonates are commonly used in clinical practice for lung cancer patients with bone metastasis to prevent skeletal-related events (SREs). The aim of this study was to evaluate the efficacy of these two bone-modifying agents(BMAs)in advanced lung cancer patients with bone metastasis in the era of immunotherapy.Methods: Electronic medical records of advanced lung cancer patients with bone metastasis between January 2020 and March 2023 were retrospectively reviewed. Overall survival (OS), progression-free survival (PFS), and the time to the first occurrence of SRE were calculated using the Kaplan - Meier method and were compared using the log-rank test.Results: Among the 227 included patients, denosumab significantly improved OS by 5.41 months compared with bisphosphonates (27.54 months vs. 22.13 months; hazard ratio (HR): 0.61; p = 0.031). Denosumab also delayed the time to the first occurrence of SRE (undefined vs. 31.64 months; HR: 0.43, p = 0.005) and reduced the incidence of multiple SREs. However, the incidence of hypocalcemia at grade ≥ 3 was higher in the denosumab group than in the bisphosphonate group (8.6% vs. 3.0%).Conclusions: In patients with bone metastatic lung cancer, the efficacy of denosumab was significantly higher than that of bisphosphonate.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2483-2493"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intravesical interferon-α2b gene therapy with nadofaragene firadenovec-vncg: a contemporary review. nadofaragene firadenovec-vncg膀胱内干扰素-α2b基因治疗：当代综述。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-10 DOI: 10.1080/14796694.2025.2527593

Taeweon Lee, Ayushi Gianchandani, Stephen A Boorjian, Neal D Shore, Vikram M Narayan, Colin P N Dinney, Ashish M Kamat

{"title":"Intravesical interferon-α2b gene therapy with nadofaragene firadenovec-vncg: a contemporary review.","authors":"Taeweon Lee, Ayushi Gianchandani, Stephen A Boorjian, Neal D Shore, Vikram M Narayan, Colin P N Dinney, Ashish M Kamat","doi":"10.1080/14796694.2025.2527593","DOIUrl":"10.1080/14796694.2025.2527593","url":null,"abstract":"Intravesical bacillus Calmette-Guerin (BCG) represents the standard of care therapy for patients with high-risk non-muscle invasive bladder cancer (NMIBC); however, the rate of BCG-unresponsive disease remains high. Cystectomy is the most definitive treatment for patients with this disease entity but is associated with significant morbidity and quality-of-life implications. Recently, several single-arm clinical trials have been conducted to develop alternative treatment options for patients who are ineligible for or decline cystectomy based on guidance from the US Food and Drug Administration (FDA). As a result, several therapeutic options have now emerged, including nadofaragene firadenovec-vncg, an intravesical gene therapy that induces interferon (IFN)-α2b gene expression with resultant direct and indirect anti-tumor effects within the bladder. Today, nadofaragene firadenovec-vncg represents the first-line treatment option for patients with BCG-unresponsive disease as an alternative to cystectomy. Advances in our knowledge of the tumor microenvironment, gene therapy techniques, and tumor biology have contributed to this important discovery, with future studies aimed to optimize the efficacy of this therapy through improved patient selection, disease prognostication, and development of combination strategies.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2429-2438"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma. 对复发和/或难治性多发性骨髓瘤患者皮下给予依沙妥昔单抗的简单语言总结。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-16 DOI: 10.1080/14796694.2025.2526281

Hang Quach, Gurdeep Parmar, Enrique M Ocio, Miles Prince, Albert Oriol, Nobuhiro Tsukada, Pierre Bories, Disa Yu, Florence Suzan, Philippe Moreau

引用次数: 0

Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor. 新开始使用派西达替尼治疗腱鞘巨细胞瘤的患者的实际经验。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-04 DOI: 10.1080/14796694.2025.2527586

Dong Dai, Kristen Tecson, Irene Pan, Xin Ye, William Tap

{"title":"Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor.","authors":"Dong Dai, Kristen Tecson, Irene Pan, Xin Ye, William Tap","doi":"10.1080/14796694.2025.2527586","DOIUrl":"10.1080/14796694.2025.2527586","url":null,"abstract":"Background: Tenosynovial giant-cell tumor (TGCT) is a rare condition characterized by pain, stiffness, and limited range of motion. Pexidartinib is the first regulatory-approved systemic therapy for adult patients with symptomatic TGCT not amenable for surgery. This study evaluated symptom improvement in patients who newly initiated pexidartinib.Methods: A longitudinal, observational study collected data on patient-reported outcomes, demographics, disease history, pexidartinib dosing, and clinicians' perspective.Results: Identified from the TURALIO Risk Evaluation and Mitigation Strategy (REMS) program, 80 patients who newly initiated pexidartinib between April and October 2022 received a study invitation, and 14 completed the baseline assessment; mean (SD) age was 39.8 (13.60) years, 50.0% were female, and most common tumor sites were in the lower extremities (71.4%). By the end of study follow-up (May 2023), 11 patients completed some PRO assessments at follow-up, and median time on pexidartinib was 7.5 months. Results showed a trend of reduction in pain and stiffness and improvement in physical functioning. Overall, 80% (8/10) endorsed moderately high treatment satisfaction with pexidartinib treatment.Conclusions: Findings from this study provided real-world evidence of an association between pexidartinib initialization and symptom improvements among patients with symptomatic TGCTs from the patients' and clinicians' perspective.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2515-2524"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

IF 2.6 4区医学

Future oncology Pub Date : 2025-07-31 DOI: 10.1080/14796694.2025.2541136

引用次数: 0